Cyklokapron
FDA Approves Dotarem, a New MRI Agent »
"The U.S. Food and Drug Administration today approved Dotarem (gadoterate meglumine) for use in magnetic resonance imaging (MRI) of the brain, spine and associated tissues of patients ages 2 years and older.
Dotarem is a gadolinium-based"...
Cyklokapron
INDICATIONS
CYKLOKAPRON (tranexamic acid) Injection is indicated in patients with hemophilia for short-term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction.
DOSAGE AND ADMINISTRATION
Immediately before tooth extraction in patients with hemophilia, administer 10 mg per kg body weight of CYKLOKAPRON (tranexamic acid) intravenously together with replacement therapy (see PRECAUTIONS). Following tooth extraction, intravenous therapy, at a dose of 10 mg per kg body weight three to four times daily, may be used for 2 to 8 days.
Note: For patients with moderate to severe impaired renal function, the following dosages are recommended:
| Serum Creatinine (µmol/L) | Tranexamic Acid I.V. Dosage |
| 120 to 250 (1.36 to 2.83 mg/dL) | 10 mg/kg BID |
| 250 to 500 (2.83 to 5.66 mg/dL) | 10 mg/kg daily |
| > 500 ( > 5.66 mg/dL) | 10 mg/kg every 48 hours or 5 mg/kg every 24 hours |
For intravenous infusion, CYKLOKAPRON (tranexamic acid) Injection may be mixed with most solutions for infusion such as electrolyte solutions, carbohydrate solutions, amino acid solutions and Dextran solutions. The mixture should be prepared the same day the solution is to be used. Heparin may be added to CYKLOKAPRON (tranexamic acid) Injection. CYKLOKAPRON (tranexamic acid) Injection should NOT be mixed with blood. The drug is a synthetic amino acid, and should NOT be mixed with solutions containing penicillin.
HOW SUPPLIED
CYKLOKAPRON (tranexamic acid) Injection 100 mg/mL
NDC 0013-1114-10 10 x 10 mL ampules
Storage
Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature].
Distributed by: Pharmacia and Upjohn Company, Division of Pfizer Inc. NY. NY. 10017.
Last reviewed on RxList: 2/17/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Cyklokapron Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Women's Health
Find out what women really need.
Updated & New
